Saltar al contenido
Merck

WRN is recruited to damaged telomeres via its RQC domain and tankyrase1-mediated poly-ADP-ribosylation of TRF1.

Nucleic acids research (2017-02-06)
Luxi Sun, Satoshi Nakajima, Yaqun Teng, Hao Chen, Lu Yang, Xiukai Chen, Boya Gao, Arthur S Levine, Li Lan
RESUMEN

Werner syndrome (WS) is a progeroid-like syndrome caused by WRN gene mutations. WS cells exhibit shorter telomere length compared to normal cells, but it is not fully understood how WRN deficiency leads directly to telomere dysfunction. By generating localized telomere-specific DNA damage in a real-time fashion and a dose-dependent manner, we found that the damage response of WRN at telomeres relies on its RQC domain, which is different from the canonical damage response at genomic sites via its HRDC domain. We showed that in addition to steady state telomere erosion, WRN depleted cells are also sensitive to telomeric damage. WRN responds to site-specific telomeric damage via its RQC domain, interacting at Lysine 1016 and Phenylalanine1037 with the N-terminal acidic domain of the telomere shelterin protein TRF1 and demonstrating a novel mechanism for WRN's role in telomere protection. We also found that tankyrase1-mediated poly-ADP-ribosylation of TRF1 is important for both the interaction between WRN and TRF1 and the damage recruitment of WRN to telomeres. Mutations of potential tankyrase1 ADP-ribosylation sites within the RGCADG motif of TRF1 strongly diminish the interaction with WRN and the damage response of WRN only at telomeres. Taken together, our results reveal a novel mechanism as to how WRN protects telomere integrity from damage and telomere erosion.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Anticuerpo anti-fosfo-histona H2A.X (Ser139), clon JBW301, clone JBW301, Upstate®, from mouse
Sigma-Aldrich
Anti-Actin (Ab-1) Mouse mAb (JLA20), liquid, clone JLA20, Calbiochem®
Sigma-Aldrich
CGK733, ≥98% (HPLC), solid
Sigma-Aldrich
MISSION® esiRNA, targeting human WRN
Sigma-Aldrich
MISSION® esiRNA, targeting human TERF1